PerkinElmer
check quantity

Streptavidin AlphaPlex™ 645 (Sm) Acceptor Beads, 250 µg

The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
AP125SM-C
250 µg
736.00 USD
 
more
AP125SM-M
5 mg
7500.00 USD
 
more
AP125SM-R
25 mg
30200.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons. These beads can be used in conjunction with Alpha Donor beads to create no-wash assays for:


  • Protein-protein interactions
  • Protein-DNA interactions
  • Protein-RNA interactions
  • Protein-small molecule interactions
  • Analyte detection
  • Biomarker detection
  • Antibody detection
  • Enzymatic assays
  • Other immunoassays

  •  

 

AlphaPlex Acceptor beads are intended to be used in multiplexing assays, in conjunction with AlphaLISA Acceptor beads and Alpha Donor beads. In a typical Alpha assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 μL reaction volume.

Specifications

Antibody Conjugates Streptavidin
Automation Compatible Yes
Bead Type or Core Bead Type AlphaPlex Samarium (645) Acceptor
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaPlex
Quantity in a Package Amount 1.0 per pack
Shipping Condition Blue Ice
Unit Size 250 µg
Resources, Events & More
  • All

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.

PDF 1 MB

Application Note

Development of Pharmacokinetic (PK) Assays for Detecting Biosimilars Targeting TNF alpha using AlphaLISA

Anti-inflammatory monoclonal antibody drugs that specifically target TNFα, such as Humira®, have been highly successful in the market. As patents expire on these top-selling drugs, effort has been placed on developing biosimilars. Biosimilars differ from small molecule generic drugs in that their chemical structure does not have to be exactly the same as the patented drug. Therefore, the FDA has stringent requirements for proving that the biosimilars have the same efficacy and safety profile as the patented drug. Companies that develop biosimilars are tasked with proving that the biosimilar shows equivalent pharmacokinetics as the patented drug.

Proving “biosimilarity” involves comparing parameters such as overall exposure, absorption, half-life, and clearance time using patient samples. Sensitive, robust, and fast assays are needed to measure these parameters. Traditional methods for detecting and quantifying these drugs in patient samples include time-consuming, wash-based ELISA and MSD methods. In contrast, AlphaLISA allows for fast, no-wash, high-throughput detection and quantification of the drug of interest in a variety of sample matrices. Here, we demonstrate the application of AlphaLISA for detecting biosimilars targeting TNFα.

PDF 2 MB
Rapid No Wash Assays for Characterizing a Mouse TIGIT/ PD-L1 Bispecific Antibody

Technical advancements in antibody engineering has brought about greater interest in more novel antibody therapeutic design and the emergence of new classes of antibody therapeutics called bispecific antibodies (bsAbs). The principle behind bispecific antibody design is to create an antibody / antibody fragment to two or more binding sites to help with the treatment of complex diseases.

As more bsAbs are produced as therapeutics, fast and accurate methods for functionally evaluating and characterizing the stability of these antibodies are necessary during both discovery and development stages, as well as during formulation and quality analysis.

In this application note, we demonstrate how AlphaLISA® assay technology with the EnVision® multimode plate reader can be used for bispecific antibody detection, through an example application to characterize the binding and specificity of a mouse bispecific antibody targeting mouse TIGIT and mouse PD-L1.

You will find out:

  • What bispecific antibodies are and how they differ from classical antibody formats
  • How to design quick and easy experiments to measure binding of the bispecific antibody to the target proteins
  • How a no-wash multiplex assay can show direct binding of each site to its respective target simultaneously in one well
  • How these assays could be used to evaluate the stability and functional reproducibility between batches of the bsAb preparations

PDF 1 MB

Brochure